Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 10
2003 10
2004 5
2005 9
2006 6
2007 10
2008 13
2009 7
2010 3
2011 9
2012 12
2013 8
2014 7
2015 2
2016 7
2017 5
2018 3
2019 7
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

114 results
Results by year
Filters applied: . Clear all
Page 1
The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer.
Iida M, Nakamura M, Tokuda E, Toyosawa D, Niwa T, Ohuchi N, Ishida T, Hayashi SI. Iida M, et al. Among authors: hayashi si. Oncotarget. 2019 Aug 6;10(47):4907-4918. doi: 10.18632/oncotarget.27127. eCollection 2019 Aug 6. Oncotarget. 2019. PMID: 31448056 Free PMC article.
Notch-Mediated Cell Adhesion.
Murata A, Hayashi S. Murata A, et al. Among authors: hayashi s. Biology (Basel). 2016 Jan 16;5(1):5. doi: 10.3390/biology5010005. Biology (Basel). 2016. PMID: 26784245 Free PMC article. Review.
Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.
Uchiumi K, Tsuboi K, Sato N, Ito T, Hirakawa H, Niwa T, Yamaguchi Y, Hayashi SI. Uchiumi K, et al. Among authors: hayashi si. Breast Cancer. 2019 Jul;26(4):459-470. doi: 10.1007/s12282-018-00944-1. Epub 2019 Jan 4. Breast Cancer. 2019. PMID: 30610551
Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M, Tsuboi K, Niwa T, Ishida T, Hayashi SI. Iida M, et al. Among authors: hayashi si. Breast Cancer. 2019 May;26(3):272-281. doi: 10.1007/s12282-018-0922-0. Epub 2018 Oct 16. Breast Cancer. 2019. PMID: 30328006
Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.
Kurozumi S, Yamaguchi Y, Matsumoto H, Kurosumi M, Hayashi SI, Fujii T, Horiguchi J, Shirabe K, Inoue K. Kurozumi S, et al. Among authors: hayashi si. PLoS One. 2019 May 21;14(5):e0217279. doi: 10.1371/journal.pone.0217279. eCollection 2019. PLoS One. 2019. PMID: 31112577 Free PMC article.
Kit-independent mast cell adhesion mediated by Notch.
Murata A, Hikosaka M, Yoshino M, Zhou L, Hayashi SI. Murata A, et al. Among authors: hayashi si. Int Immunol. 2019 Feb 15;31(2):69-79. doi: 10.1093/intimm/dxy067. Int Immunol. 2019. PMID: 30299470
Mechanisms of hormonal therapy resistance in breast cancer.
Hayashi S, Kimura M. Hayashi S, et al. Int J Clin Oncol. 2015 Apr;20(2):262-7. doi: 10.1007/s10147-015-0788-5. Epub 2015 Feb 5. Int J Clin Oncol. 2015. PMID: 25652907 Review.
Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer.
Kimura M, Hanamura T, Tsuboi K, Kaneko Y, Yamaguchi Y, Niwa T, Narui K, Endo I, Hayashi SI. Kimura M, et al. Among authors: hayashi si. Oncotarget. 2018 Apr 20;9(30):21468-21477. doi: 10.18632/oncotarget.25133. eCollection 2018 Apr 20. Oncotarget. 2018. PMID: 29765553 Free PMC article.
Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
Iida M, Toyosawa D, Nakamura M, Tsuboi K, Tokuda E, Niwa T, Ishida T, Hayashi SI. Iida M, et al. Among authors: hayashi si. Breast Cancer. 2020 Sep;27(5):963-972. doi: 10.1007/s12282-020-01090-3. Epub 2020 Apr 15. Breast Cancer. 2020. PMID: 32297248
114 results
Jump to page
Feedback